Aggression in autism spectrum disorder: presentation and treatment options
暂无分享,去创建一个
C. Erickson | E. Pedapati | Logan K Wink | Sarah E. Fitzpatrick | Sarah E Fitzpatrick | Laura Srivorakiat | Ernest V Pedapati | Craig A Erickson | Logan K. Wink | Laura Srivorakiat
[1] M. Weiss,et al. Treatment of severe aggression in an adolescent with autism: Non-contingent Reinforcement and Functional Communication Training. , 2004 .
[2] C. McDougle,et al. Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study , 2015, Autism : the international journal of research and practice.
[3] C. McDougle,et al. A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder. , 2015, Journal of child and adolescent psychopharmacology.
[4] L. Lecavalier,et al. The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. , 2006, Journal of intellectual disability research : JIDR.
[5] Angel Fettig,et al. Evidence-Based Practices for Children, Youth, and Young Adults with Autism Spectrum Disorder: A Comprehensive Review , 2015, Journal of autism and developmental disorders.
[6] C. McDougle,et al. Pharmacotherapy of irritability in pervasive developmental disorders. , 2008, Child and adolescent psychiatric clinics of North America.
[7] R. Findling,et al. Lurasidone for the Treatment of Irritability Associated with Autistic Disorder , 2015, Journal of Autism and Developmental Disorders.
[8] Hannah F Jones,et al. Antiepileptics for aggression and associated impulsivity. , 2010, The Cochrane database of systematic reviews.
[9] A. Ghanizadeh,et al. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders , 2013, BMC Psychiatry.
[10] M. Bauer,et al. The suicide prevention effect of lithium: more than 20 years of evidence—a narrative review , 2015, International Journal of Bipolar Disorders.
[11] C. Erickson,et al. Memantine for disruptive behavior in autistic disorder. , 2006, The Journal of clinical psychiatry.
[12] G. Arbanas. Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .
[13] E. Cook,et al. Aggression in children with autism spectrum disorders and a clinic-referred comparison group , 2015, Autism : the international journal of research and practice.
[14] H. Demb,et al. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. , 2006, Journal of child and adolescent psychopharmacology.
[15] Kelli C. Dominick,et al. Atypical behaviors in children with autism and children with a history of language impairment. , 2007, Research in developmental disabilities.
[16] Timothy J. Lewis,et al. Functional Behavioral Assessment , 2004 .
[17] P. Sturmey,et al. Behaviour Management Problems as Predictors of Psychotropic Medication and Use of Psychiatric Services in Adults with Autism , 2007, Journal of autism and developmental disorders.
[18] H. Duggal. Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder. , 2007, Journal of child and adolescent psychopharmacology.
[19] J. Waizer,et al. A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children , 1973, Journal of autism and childhood schizophrenia.
[20] M. Mohammadi,et al. Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism: A 10-Week Randomized Study , 2013, Clinical neuropharmacology.
[21] C. McDougle,et al. Paliperidone for irritability in adolescents and young adults with autistic disorder , 2012, Psychopharmacology.
[22] J. E. Carr,et al. Functional Assessment of Problem Behavior in Children with Autism Spectrum Disorders: A Summary of 32 Outpatient Cases , 2009, Journal of autism and developmental disorders.
[23] F. Aubin,et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.
[24] C. McDougle,et al. A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders , 2016, Molecular Autism.
[25] Sandra M. Stith,et al. Risk factors in child maltreatment: A meta-analytic review of the literature. , 2009 .
[26] C. McDougle,et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. , 2009, Journal of child and adolescent psychopharmacology.
[27] G. Gobbi,et al. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. , 2001, Journal of psychiatry & neuroscience : JPN.
[28] M. Siegel,et al. Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. , 2014, Journal of child and adolescent psychopharmacology.
[29] C. McDougle,et al. Pharmacotherapy of Autism and Related Disorders , 2007 .
[30] M. Campbell,et al. Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. , 1995, Psychopharmacology bulletin.
[31] L. Hagopian,et al. An analysis of functional communication training as an empirically supported treatment for problem behavior displayed by individuals with intellectual disabilities. , 2011, Research in developmental disabilities.
[32] J. E. Carr,et al. A review of "noncontingent" reinforcement as treatment for the aberrant behavior of individuals with developmental disabilities. , 2000, Research in developmental disabilities.
[33] C. Weston,et al. Physical Intervention with People with Intellectual Disabilities: The Influence of Cognitive and Emotional Variables. , 2006 .
[34] R. Perry,et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children , 1989, Journal of autism and developmental disorders.
[35] D. Wacker,et al. Conducting Functional Communication Training in Home Settings: A Case Study and Recommendations for Practitioners , 2009, Behavior analysis in practice.
[36] S. Al-Saad,et al. Olanzapine in the Treatment of Behavioral Problems Associated with Autism: An Open-Label Trial in Kuwait , 2008, Medical Principles and Practice.
[37] Kelly M. Schieltz,et al. Indirect Effects of Functional Communication Training on Non-Targeted Disruptive Behavior , 2011, Journal of behavioral education.
[38] B. Iwata,et al. Toward a functional analysis of self-injury. , 1994, Journal of applied behavior analysis.
[39] C. McDougle,et al. Aripiprazole for maladaptive behavior in pervasive developmental disorders. , 2004, Journal of child and adolescent psychopharmacology.
[40] C. McDougle,et al. Multiple Antipsychotic Medication Use in Autism Spectrum Disorder. , 2017, Journal of child and adolescent psychopharmacology.
[41] R. Mcquade,et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. , 2011, Journal of child and adolescent psychopharmacology.
[42] A. Richdale,et al. Functional communication training to replace challenging behaviors across two behavioral outcomes , 2000 .
[43] O. Guillin,et al. Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. , 2010, Journal of child and adolescent psychopharmacology.
[44] O. Guillin,et al. Retrospective Review of Clozapine in the Treatment of Patients With Autism Spectrum Disorder and Severe Disruptive Behaviors , 2011, Journal of clinical psychopharmacology.
[45] C. Correll,et al. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. , 2011, Journal of child and adolescent psychopharmacology.
[46] W. Arsenio,et al. Trajectories of physical aggression from toddlerhood to middle childhood: predictors, correlates, and outcomes. , 2004, Monographs of the Society for Research in Child Development.
[47] R. Mccoy,et al. Prevalence and risk factors of maladaptive behaviour in young children with Autistic Disorder. , 2008, Journal of intellectual disability research : JIDR.
[48] E. Cook,et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. , 2005, Journal of child and adolescent psychopharmacology.
[49] Mark J. Palmieri,et al. Evidence-Based Treatment of Behavioral Excesses and Deficits for Individuals with Autism Spectrum Disorders , 2011 .
[50] M. Mohammadi,et al. Riluzole as an Adjunctive Therapy to Risperidone for the Treatment of Irritability in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial , 2013, Pediatric Drugs.
[51] S. Hall,et al. Risk markers associated with challenging behaviours in people with intellectual disabilities: a meta-analytic study. , 2003, Journal of intellectual disability research : JIDR.
[52] C. B. Ferster. Positive reinforcement and behavioral deficits of autistic children. , 1961, Child development.
[53] J. Matson,et al. The Effects of Severity of Autism and PDD-NOS Symptoms on Challenging Behaviors in Adults with Intellectual Disabilities , 2008 .
[54] C. McDougle,et al. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. , 2005, The American journal of psychiatry.
[55] C. McDougle,et al. The Pharmacotherapy of Target Symptoms Associated with Autistic Disorder and Other Pervasive Developmental Disorders , 2000, Harvard review of psychiatry.
[56] C. Correll,et al. Safety and tolerability of antipsychotic polypharmacy , 2012, Expert opinion on drug safety.
[57] J. Overall,et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. , 1989, Journal of the American Academy of Child and Adolescent Psychiatry.
[58] R. Findling,et al. Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder , 2009, Pediatrics.
[59] R. Caplan,et al. The effects of haloperidol on learning and behavior in autistic children , 1982, Journal of autism and developmental disorders.
[60] C. Scheiner. Evidence-based Practices and Treatments for Children with Autism , 2013 .
[61] B. Iwata,et al. Functional analysis screening for problem behavior maintained by automatic reinforcement. , 2013, Journal of applied behavior analysis.
[62] C. McDougle,et al. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.
[63] C. McDougle,et al. Aripiprazole in autism spectrum disorders and fragile X syndrome , 2010, Neurotherapeutics.
[64] B. Poyraz,et al. Rapid Clozapine Titration in Patients with Treatment Refractory Schizophrenia , 2016, Psychiatric Quarterly.
[65] E. Hollander,et al. Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis , 2013, Journal of Autism and Developmental Disorders.
[66] F. Naeem,et al. Clozapine for psychotic disorders in adults with intellectual disabilities. , 2015, The Cochrane database of systematic reviews.
[67] J. Luiselli. Aggression and Noncompliance , 2009 .
[68] C. McDougle,et al. Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.
[69] L. Bender. Aggression in children. , 1974, Research publications - Association for Research in Nervous and Mental Disease.
[70] M. Mohammadi,et al. N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety , 2015, Clinical neuropharmacology.
[71] I. Cohen,et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. , 1978, Journal of the American Academy of Child Psychiatry.
[72] I. Smith,et al. Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders , 2004, Pediatrics.
[73] R. Mcquade,et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.
[74] C. Mazure,et al. Clozapine in the treatment of aggression in an adolescent with autistic disorder. , 2001, The Journal of clinical psychiatry.
[75] Jonathan M. Campbell,et al. Comparing Functional Assessment Methodologies: A Quantitative Synthesis , 2007, Journal of autism and developmental disorders.
[76] J. Belmont,et al. Functional Characteristics of Disruptive Behavior in Developmentally Disabled Children with and without Autism , 2005, Journal of autism and developmental disorders.
[77] Fabian T. Camacho,et al. Psychotropic medication trends among children and adolescents with autism spectrum disorder in the Medicaid program , 2014, Autism : the international journal of research and practice.
[78] C. McDougle,et al. The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. , 2012, Journal of child and adolescent psychopharmacology.
[79] M. Berk,et al. The promise of N-acetylcysteine in neuropsychiatry. , 2013, Trends in pharmacological sciences.
[80] J. M. Otero-López,et al. Job dissatisfaction and burnout in secondary school teachers: student's disruptive behaviour and conflict management examined , 2009 .
[81] John Lally,et al. Antipsychotic medication in schizophrenia: a review. , 2015, British medical bulletin.
[82] A. Hardan,et al. A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with Autism , 2012, Biological Psychiatry.
[83] David Taylor. Ziprasidone in the Management of Schizophrenia , 2003, CNS drugs.
[84] C. McDougle,et al. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. , 2015, Journal of child and adolescent psychopharmacology.
[85] L. J. Barnhill,et al. Olanzapine in PDD. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.
[86] H. van Engeland,et al. Open-Label Study of Olanzapine in Children with Pervasive Developmental Disorder , 2002, Journal of clinical psychopharmacology.
[87] B. Iwata,et al. Reliability and validity of the functional analysis screening tool. , 2013, Journal of applied behavior analysis.
[88] R. Findling,et al. Quetiapine in nine youths with autistic disorder. , 2004, Journal of child and adolescent psychopharmacology.
[89] A. Hardan,et al. Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders , 2005, Journal of autism and developmental disorders.
[90] Stepan Melnyk,et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[91] W. Fisher,et al. Lithium Carbonate in the Treatment of Two Patients with Infantile Autism and Atypical Bipolar Symptomatology , 1987, Journal of clinical psychopharmacology.
[92] J. Blacher,et al. Preschool children with intellectual disability: syndrome specificity, behaviour problems, and maternal well-being. , 2005, Journal of intellectual disability research : JIDR.
[93] K. Puura,et al. Reactive aggression among children with and without autism spectrum disorder , 2014, Journal of autism and developmental disorders.
[94] Ş. Turan,et al. Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series , 2015, Therapeutic advances in psychopharmacology.
[95] A. Roy,et al. Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. , 2015, Journal of intellectual disability research : JIDR.
[96] C. McDougle,et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. , 2004, The Journal of clinical psychiatry.
[97] M. Ernst,et al. Naltrexone in autistic children: behavioral symptoms and attentional learning. , 1993, Journal of the American Academy of Child and Adolescent Psychiatry.
[98] J. Matson,et al. Questions about behavioral function (QABF): a behavioral checklist for functional assessment of aberrant behavior. , 2000, Research in developmental disabilities.
[99] C. McDougle,et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. , 1999, Journal of clinical psychopharmacology.
[100] J. Panksepp,et al. Possible Brain Opioid Involvement in Disrupted Social Intent and Language Development of Autism , 1987 .
[101] S. Green,et al. Parenting stress and child behavior problems: a transactional relationship across time. , 2012, American journal on intellectual and developmental disabilities.
[102] R. Malone,et al. Ziprasidone in adolescents with autism: an open-label pilot study. , 2007, Journal of child and adolescent psychopharmacology.
[103] Deepmala,et al. Neuroscience and Biobehavioral Reviews Clinical Trials of N-acetylcysteine in Psychiatry and Neurology: a Systematic Review , 2022 .
[104] M. Mohammadi,et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. , 2013, The international journal of neuropsychopharmacology.
[105] J. Leon,et al. Clozapine for treatment‐resistant bipolar disorder: a systematic review , 2015, Bipolar disorders.
[106] K. Maich,et al. Applied Behavior Analysis , 2018, Reference Module in Neuroscience and Biobehavioral Psychology.
[107] Terry S. Falcomata,et al. A comparison of methodologies of brief functional analysis , 2015, Developmental neurorehabilitation.
[108] Micah O. Mazurek,et al. Aggression in Children and Adolescents with ASD: Prevalence and Risk Factors , 2011, Journal of autism and developmental disorders.
[109] C. McDougle,et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. , 1998, Archives of general psychiatry.
[110] J. Bregman,et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. , 1999, Journal of child and adolescent psychopharmacology.
[111] Florence D. DiGennaro Reed,et al. A Meta-Analysis of Behavioral Interventions for Adolescents and Adults with Autism Spectrum Disorders , 2014 .
[112] E. Carr,et al. Reducing behavior problems through functional communication training. , 1985, Journal of applied behavior analysis.
[113] E. Hollander,et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. , 2006, Journal of child and adolescent psychopharmacology.
[114] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[115] J. Biederman,et al. Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. , 1987, Journal of the American Academy of Child and Adolescent Psychiatry.
[116] Dennis R. Dixon,et al. Assessing and treating aggression in children and adolescents with developmental disabilities: a 20‐year overview , 2005 .
[117] L. J. Barnhill,et al. Risperidone and Explosive Aggressive Autism , 1997, Journal of autism and developmental disorders.
[118] C. McDougle,et al. Riluzole in autistic disorder. , 2011, Journal of child and adolescent psychopharmacology.
[119] E. Cook,et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. , 2005, Journal of child and adolescent psychopharmacology.
[120] R. Hastings,et al. Systems Analysis of Stress and Positive Perceptions in Mothers and Fathers of Pre-School Children with Autism , 2005, Journal of autism and developmental disorders.
[121] C. McDougle,et al. Paliperidone for irritability in autistic disorder. , 2010, Journal of child and adolescent psychopharmacology.
[122] L. Zwaigenbaum,et al. Home Sweet Home? Families’ Experiences With Aggression in Children With Autism Spectrum Disorders , 2013 .
[123] C. Correll,et al. Rapid clozapine titration in treatment-refractory bipolar disorder. , 2014, Journal of affective disorders.
[124] J. Korein,et al. Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children , 1972, Journal of autism and childhood schizophrenia.
[125] M. Bear,et al. STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study , 2014, Journal of autism and developmental disorders.
[126] H. Goforth,et al. Improvement in behaviour and attention in an autistic patient treated with ziprasidone. , 2003, Australian and New Zealand journal of psychiatry (Print).